Scan how ResMed's move into virtual sleep care compares with other potential beneficiaries of remote diagnostics by reviewing our curated list of 37 healthcare AI stocks.
To own ResMed, you have to believe its sleep and breathing health platform can keep pulling more patients into diagnosis and long term digital monitoring. The analyst consensus Narrative on Simply Wall St leans on steady mid single digit revenue growth, high quality earnings and scope for margins to stay healthy. The VirtuOx deal fits neatly into that story by deepening virtual diagnosis and data capture rather than changing it.
In the near term, the key swing factor still sits with execution on supply costs, Astral remediation and replacing MatrixCare revenue, not VirtuOx. Astral corrective actions, freight and component inflation and the hole left by MatrixCare are the main operational risks flagged. If remediation drags or the refocused software portfolio underdelivers, the margin and earnings profile that underpins the current narrative could soften.
The VirtuOx acquisition stands out as the announcement most tied to this virtual sleep clinic theme. VirtuOx adds at home sleep testing and monitoring capacity that plugs straight into ResMed’s existing connected devices and platforms like AirView and myAir. That combination is intended to pull diagnosis earlier, then keep more patients inside ResMed’s ecosystem over time.
For you as an investor, the interesting angle is how this deepens the diagnosis funnel that analysts already view as a core catalyst. More virtual testing can support device and mask demand, while the digital tools are designed to sustain adherence and resupply, which matters for recurring revenue. The opportunity sits beside risks such as Astral and inflation, so the focus now is on how cleanly ResMed executes the integration and maintains margin discipline while virtual volumes scale.
ResMed's current analyst narrative focuses on revenues of US$6.7b and earnings of US$2.0b by 2029, based on 5.4% yearly revenue growth and an earnings increase of about US$400m from the US$1.6b reported today.
Uncover why ResMed's fair value indicates a 9% potential upside to its current price, which could narrow quickly.
You might see ResMed very differently if you lean into the bullish catalyst around higher digital adherence. The most optimistic analysts were already pencilling in revenue of about US$7.2b and earnings of US$2.2b by 2029 before this VirtuOx news, so a bigger virtual sleep clinics market could push those narratives to evolve further.
Explore 4 other ResMed fair value estimates, including one that suggests potential upside of up to 50% from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
If the VirtuOx deal has you rethinking how ResMed fits into your portfolio, it can be useful to line it up against other opportunities that share traits you care about, whether that is quality, income or resilience.
The Simply Wall St Screener makes it straightforward to sift through hundreds of alternatives using the same data driven approach behind this analysis. A few quick angles to consider are:
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com